- 1 Concord Cancer Hospital Singapore and MD Anderson Cancer Center Jointly Held Oncology Nursing Workshop 收起>>
During the period from July 11th to 14th 2016,Concord Cancer Hospital Singapore and MD Anderson Cancer Center, a top cancerhospital in the US, jointly held a five-day workshop on oncology nursing inSingapore.
Katherine Mishaw, Nurse Educator, Cancer Network, from MD Anderson Cancer Center presented a detailed and enlightening lecture to all theparticipants.
Toni Abbasi, Executive Director of Projects and Operations from MDAnderson Cancer Center also attended.
- 2 Concord Medical Services Signs Multi-year Strategic Collaboration Agreement with MD Anderson Cancer Center 收起>>
Exclusive Collaboration at Concord’s New Cancer Facilities in Shanghai and Beijing, China and in Singapore
BEIJING, May 6, 2015 -- Concord Medical Services Holdings Limited ("CCM" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has signed a multi-year strategic development agreement with The University of Texas MD Anderson Cancer Center (MD Anderson”), an internationally renowned cancer research, treatment and education center. CCM and MD Anderson will collaborate to develop a multidisciplinary cancer care, subspecialized and research-driven oncology program and state-of-art oncology facilities to optimize patient experience and improve cancer care in China and Singapore.
MD Anderson will provide CCM with strategic counsel and programmatic services to support the development and implementation of a multidisciplinary oncology program with emphasis on clinical quality, patient safety, training and education, as well as research and development programs. The agreement, which is the first of its kind for MD Anderson in Asia, will be an exclusive collaboration at CCM’s new cancer facilities in Shanghai and Beijing, and the collaboration exclusivity will cover most of the provinces in China, and in Singapore. The organizations will also work collaboratively as CCM develops a new cancer hospital in Guangzhou, China.
In the future, CCM’s cancer hospitals in China and Singapore will pursue to qualify for MD Anderson Cancer Network’s Associate membership program, a co-branded clinical care, research and delivery partnership, which includes clinical integration with MD Anderson.
“We are very pleased to enter into a comprehensive, exclusive collaboration with M.D. Anderson,” commented Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical. “M.D. Anderson, one of the leading cancer hospitals in the U.S., represents the highest standard in cancer treatment and diagnosis. We intend to work together with MDACC’s clinical and management teams to introduce MDACC’s multidisciplinary treatment and other advanced methodologies, treatment regimens, academic achievements as well as advanced technologies for the benefit of patients in China and Singapore. We also intend to cooperate in research related to high incidence oncology diseases in China, as well as provide international training standards to doctors and research personnel.” concluded Dr. Yang.
“There is a significant gap in the quality of treatment and care to cancer patients between the U.S. and China. Through our collaboration with MD Anderson, Concord Medical will continue to enhance its overall standard of care to cancer patients in China,” Yang said.
“Collaboration is vital to realizing our mission of eliminating cancer worldwide. We’re pleased to expand our long-standing relationship with Concord Medical and help develop a multidisciplinary, research-driven oncology program,” said Dan Fontaine, MD Anderson’s Executive Chief of Staff. “Together, we’ll work to fight cancer across China and Singapore.”
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation's top two cancer centers in U.S. News & World Report's annual "Best Hospitals" survey.
- 3 Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 收起>>
March 27, 2015 Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced the signing of a purchase agreement under which Concord Medical Services (International) Pte Ltd, a wholly owned subsidiary of the Company, agreed to acquire the Fortis Surgical Hospital from Fortis Healthcare International Pte Ltd, a subsidiary of Fortis Healthcare Ltd (Fortis). The acquisition will be a 100% cash transaction, for a consideration of SGD55 million (USD39.8 million*), and has been approved by the Boards of both parties. Concord Medical expects to close the deal on or about April 6th, 2015.
Fortis Surgical Hospital is a private facility in Singapore that is established in July 2012, currently with 31 bed patient capacity. Fortis Surgical Hospital (FSH) specializes in minimally invasive procedures and offers the full spectrum of clinical interventions including laparoscopic and robot-assisted surgeries. Close to 100 robot-assisted surgical procedures have so far been successfully performed at the hospital. The acquisition of Fortis Surgical Hospital (FSH) brings together the expertise of renowned surgeons in the delivery of advanced surgical procedures in colorectal, urology, gynecology, plastic and general Surgeries.
After the acquisition, CCM will start the application to Singapore's Ministry of Health (MOH) to change the FSH name into Singapore Concord Cancer Hospital, and to add more medical specialties (e.g. oncology, cardiology, respiratory, dermatology, renal medicine, endocrinology radiotherapy, and robot-assisted surgery).
"We are very pleased to welcome Singapore Concord Cancer Hospital to the CCM family," Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented. "After the completion of the acquisition, Singapore Concord Cancer Hospital will be integrated into CCM's hospital network and extension of oversees business. We plan to build Singapore Concord Cancer Hospital into a platform for high-end medical treatment institution that include academic research and cooperation for the Singapore patients as well as for patients coming from China, who currently are seeking overseas treatment."
"The acquisition is part of our high-end cancer hospital development strategy. Singapore Concord Cancer Hospital will be complementary with the hospitals we are currently building in Shanghai, Guangzhou, and Beijing. We will cooperate with the international top cancer hospital to provide treatment which is synchronous with the international latest technology at any time in this hospital, meeting the needs of high-end patients in Asia."
* translation of Singapore dollar amount into U.S. dollar amount is made at a rate of SGD1.3823 to US$1.00, the effective noon buying rate as of March 20, 2015, as set forth in the H.10 statistical release of the U.S. Federal Reserve Board.
- 4 CCM Receives Approval to Establish Free-Standing Radiotherapy Center in Datong 收起>>
BEIJING, Oct. 27, 2014 -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), an operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, today announced that the Company has received relevant government approvals to establish a free-standing radiotherapy cancer center, Datong Meizhong Jiahe Cancer Center ("Datong Center") in Datong City, Shanxi Province.
Datong Center, a 100%-owned subsidiary of Concord Medical, will provide advanced, best-practice diagnostic and radiotherapy services with 100 beds once the construction of the facility is completed. It will be the first free-standing center in the Concord Medical network. Construction is expected to begin in November 2014 and the center will be operational in 2015. The center will be registered as a specialty cancer hospital with required departments, including radiation, imaging, test laboratory, inpatient, and nursing. This center will apply to join the local social insurance coverage. This free-standing center facility is an important step of the Company's broader strategy to build a nationwide chain of free-standing cancer treatment and diagnosis centers in the future.
Datong City is located 350 kilometers west of Beijing and is considered the "Coal Capital" of China. It is the commercial and industrial hub of Shanxi Province, with a population of 3.35 million in the city and over 7 million people in the neighboring areas. According to Datong Health Bureau, in 2012 cancer accounted for 30.03% of the total number of deaths in Datong. The top-3 male cancer incidences were lung cancer (38.71%), stomach cancer (12.06%), and liver tumors (9.85%). The top-3 female cancer incidences were breast cancer (20.02%), bronchus and lung cancer (10.66%), and cervical cancer (10.45%).
Dr. Jianyu Yang, Chairman and CEO of Concord Medical, commented, "We are very pleased to announce our first free-standing radiotherapy cancer center. This is a significant step in our plan to open a network of free-standing centers that provide diagnosis and radiotherapy services. Datong City represents a strategic opportunity for our first free-standing center. Currently, we are managing a radiotherapy center in a local hospital in Datong, where we have good doctor resources and a strong market network. We intend to utilize our existing resources to provide the highest quality of radiotherapy services for patients."
"In the coming years, we plan to selectively transform our current centers within existing hospitals into free-standing self-owned centers," concluded Dr. Yang. "As healthcare reform is implemented in China, we will capitalize on the opportunity and rely on our technical advantages and experience to expand our free-standing radiotherapy cancer center network in areas in which we have existing resources and strong patient demand."
- 5 MD Anderson Proton Therapy Center Board of Directors Meeting in Beijing 收起>>
BEIJING, Aug. 15, 2014 -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading hospital management company and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that the MD Anderson Proton Therapy Center (MDACC PTC) held a meeting of its board of directors in Concord Medical's Beijing office on August 11, 2014. Participants of the board meeting included members of the board of directors of MDACC PTC, members of the Advisory Board of MDACC PTC as well as management teams from both the Company and MDACC. CCM holds 19.98% ownership of the MDACC PTC since December 2012.
- 6 CCM Signs Consulting Agreement with MD Anderson Cancer Center 收起>>
BEIJING, May 16, 2014 -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced it has engaged The University of Texas MD Anderson Cancer Center ("MD Anderson") as a consultant for its cancer hospital projects under planning in Shanghai and Beijing.
According to the agreement, MD Anderson will provide consulting services to Concord Medical with respect to the enhancement of its cancer care program for the Company's two projects, Shanghai Concord Cancer Hospital and Beijing Concord Cancer Hospital, which will be located in Shanghai New Hongqiao International Medical Center and Beijing International Medical Center, respectively. This agreement is an arm's-length contract at regular commercial terms.
The consulting agreement is part of Concord Medical's collaboration with MD Anderson to bring the best practice in cancer treatment to China. Through the collaboration, MD Anderson will provide technical management and medical support to Concord Medical's cancer hospitals. The analyses and recommendations MD Anderson provides Concord Medical will be based on MD Anderson's unique expertise in the appropriate utilization, applicability, and suitability of various modalities in the treatment of cancer using a multi-disciplinary approach.
Concord Medical acquired 19.98% ownership of The MD Anderson Proton Therapy Center in Houston, Texas at the end of 2012.
Shanghai Concord Cancer Hospital plans to open 400 beds and adapt the domestic and internationally advanced therapeutic methods, medical process and management system. It plans to install the most advanced cancer diagnostic and treatment equipment and multidiscipline system. When completed, the hospital will become a leading cancer hospital in China and Asia.
Beijing Concord Cancer Hospital will be wholly owned by Concord Medical and will provide comprehensive cancer therapies, including surgery, chemotherapy, radiotherapy, and gene therapy to cancer patients. Concord Medical will provide management support, treatment, technology, and research to the hospital, including protocols and clinical practice guidelines, by collaborating with top-notch cancer institutions around the world. Beijing Concord Cancer Hospital will be part of Beijing International Medical Center (BIMC), a joint project initiated by Beijing municipal government, the Ministry of Health, and several other Chinese government agencies to introduce world-standard medical services to China.
Dr. Jianyu Yang, the Chairman and CEO of Concord Medical, said, "We are very pleased to have MD Anderson provide strategic consulting services for our Beijing and Shanghai hospital projects. MD Anderson is an internationally renowned cancer research, treatment, and education center and our collaboration will deliver to Concord Medical the substantial knowledge and expertise in appropriate development and operation of oncology programs for the treatment of patients."
"MD Anderson's mission is to eliminate cancer across the world and we welcome this opportunity to collaborate with a prestigious organization like Concord Medical to elevate the quality of cancer care in China," said Amy Hay, MD Anderson's Vice President of Business Development.
- 7 CCM Received Approval to Build Shanghai Concord Cancer Hospital 收起>>
BEIJING, April 4, 2014 -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced the Company will establish Shanghai Concord Cancer Hospital ("Shanghai Concord") - a premium cancer hospital - in Shanghai New Hongqiao International Medical Center.
Shanghai Concord plans to open 400 beds and adapts the domestic and internationally advanced therapeutic methods, medical process and management system. It plans to install the most advanced cancer diagnosis and treatment equipment and multidiscipline system. When completed, the hospital will become a leading cancer hospital in China and Asia.
So far, the Company has received the relevant government approval for the establishment of Shanghai Concord. The Company is in the process of finalizing the design and other pre-construction work. The construction is scheduled to start in the first half of 2015. The total construction period will be three years.
Recently, the Chinese government has issued several policies to encourage social capital into the healthcare services industry, including "Several Opinions to Accelerate the Social Investment in Healthcare Services" and "The State Council's Several Opinions to Promote the Development of the Healthcare Services Industry". By 2015, China's non-public medical institution beds and services will reach 20% of the total number of medical institutions. Local governments also have issued relevant detailed rules for the implementation. The approval process for setting up private medical institutions is clarified gradually. Healthcare services will become a new major growth sector in China's economy.
In early 2013, the National Cancer Registry Center released the latest version of the "2012 Chinese Cancer Registry Annual Report", showing that China's new cancer cases are about 3.12 million and cancer deaths are more than 2 million annually. By 2020, China will have a total of 4 million new cases and a total of 6 million cancer patients each year. Cancer has become a major challenge facing China's healthcare industry.
Based on 17-year experience in cancer treatment and diagnosis, Concord Medical will introduce the most advanced cancer diagnosis and treatment equipment, cooperate with the international renowned medical institutions, innovate the hospital operation management mode, and fully motivate the enthusiasm of doctors.
"The establishment of specialized, premium cancer hospital is an important component of our development strategy and also is highly consistent with the Chinese government policies encouraging private capital to enter the medical service industry." Dr. Jianyu Yang, the Chairman and CEO of Concord Medical, said, "As the most economically developed area in China, Shanghai possesses the most abundant medical and human resources in China. It is a very significant milestone for Concord Medical to build a leading cancer hospital in Shanghai."
Dr. Jianyu Yang also said, "During the process, we have received strong support and guidance from Shanghai New Hongqiao International Medical Center, which represent a new direction for China's healthcare reform. After the construction of Shanghai Concord Cancer Hospital is completed, Concord Medical will become a leading hospital group, including cancer hospitals in Shanghai and Guangzhou and more than 140 existing cancer diagnosis and radiotherapy centers covering the whole country."
About Shanghai New Hongqiao International Medical Center:
Shanghai New Hongqiao International Medical Center is a high-end medical services project, supported by the Ministry of Health and approved by Shanghai Municipal People's Government. The total planning area of the Medical Center is approximately 100 hectares, and the planning land area of the First Phase is 42.38 hectares. The project will focus on providing high-end medical services, attracting diversified investments from international and private sources. It will explore innovative and integrated healthcare delivery model, including medical service, technical support, managerial collaboration and supply-chain extension. The NHQ Center will attract the participations of domestic and overseas high-quality medical institutions and managerial talent, create a Shanghai-based platform radiating throughout the Yangtze River Delta and the entire country. The construction of Shanghai New Hongqiao International Medical Center was officially launched on March 30, 2012. The First Phase of the Medical Center is expected to be fully operational in 2015. For more information, please visit http://www.nhqmed.com/.